Drug stocks down, Boston Scientific falls on study
14th Nov 2006, 18:36 GMT
SAN FRANCISCO (MarketWatch) -- Drug stocks were lower in Tuesday afternoon trading, and shares of Boston Scientific Corp. fell in the wake of a new study that questioned the effectiveness of using stents in some heart attack patients.
Drug stocks down, Boston Scientific falls on study related news:
- Boston Scientific shares fall on study — Boston.com / News
- Study may boost bare-metal stents — Boston Globe -- Business News
- Sepracor says asthma drug data is favorable — Latest news from Boston Business Journal
- Stocks rise as oil falls (Reuters) — Yahoo! News: Business
- Drug stocks pare gains; Solexa, Isis shares soar — MarketWatch.com - Top Stories – Sponsored by: CyberTrader
- Stocks climb as oil falls (Reuters) — Yahoo! News: Stock Markets News
- Boston Scientific and Univ of Akron Expand License Agreement for Use of UA Polymers in Medical Devices — StratWire - Business of Healthcare NewsFeed
- Diabetes drug may cut heart risks: study (Reuters) — Yahoo! Health: Health News
- Diabetes drug may cut heart risks: study — Reuters: Health
- Tech stocks find momentum; Agilent falls on earnings — MarketWatch.com - Software Industry News
Latest news from MarketWatch.com - Top Stories – Sponsored by: CyberTrader:
- Toyota plans for 15% global market share by 2010
- Tokyo shares lead region lower; Mining shares tumble in Sydney
- Google's builds a premium feature, one page at a time
- The L.A. Times is dying by a thousand cuts
- Dines' day dawning?
- KB Home CEO resigns after backdating probe
- Drug stocks pare gains; Solexa, Isis shares soar
- Solexa's shares soar on $600 million buyout by Illumina
- Isis Pharma's shares soar on cholesterol-drug Phase II data
- D.R. Horton's profit seen lower with key housing data on tap